Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,459 matching trials from the live ClinicalTrials.gov search.
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions
UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization
Device
Lead sponsor
St. Louis University
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Terminated No phase listed Observational

PTNS vs Botox of Refractory OAB

NCT04451382
Conditions
Overactive Bladder (OAB)
Interventions
OnabotulinumtoxinA (BoNTA), Percutaneous tibial nerve stimulation (PTNS)
Biological · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Conditions
Stress Urinary Incontinence
Interventions
duloxetine HCl
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Stress Urinary Incontinence
Interventions
Neurotech Vital Compact, itouch Sure Pelvic Floor Exerciser
Device
Lead sponsor
Atlantic Therapeutics
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Hartford, Connecticut + 9 more
Conditions
Cancer
Interventions
TTX-080, pembrolizumab, cetuximab, FOLFIRI
Drug
Lead sponsor
Tizona Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
41
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 37 more
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
Exercise, Calls and Newsletter
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Francisco, California
Conditions
Overactive Bladder
Interventions
Solabegron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Active, not recruiting No phase listed Observational

Continence Care Registry

NCT04924569
Conditions
Neurogenic Bladder, Non-Neurogenic Bladder
Interventions
Not listed
Lead sponsor
Hollister Incorporated
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Libertyville, Illinois
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Conditions
Stress Urinary Incontinence
Interventions
onabotulinumtoxin A
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Interstitial Cystitis: Examination of the Central Autonomic Network

NCT03008382
Conditions
Interstitial Cystitis/Painful Bladder Syndrome, Myofascial Pelvic Pain
Interventions
Metoprolol Tartrate Oral Tablet, Placebo Oral Tablet, No intervention- observational sub-study
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Evanston, Illinois • Richmond, Virginia
Conditions
Pelvic Floor Injury, Urinary Incontinence, Stool Incontinence
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Conditions
Bladder Cancer
Interventions
Ethacrynic Acid
Drug
Lead sponsor
Eugene Lee, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Urinary Incontinence, Intrinsic Sphincter Deficiency
Interventions
Needle Guided Periurethral Injection
Device
Lead sponsor
Carbon Medical Technologies
Industry
Eligibility
Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Jacksonville, Florida • West Chester, Ohio
Terminated Phase 3 Interventional Accepts healthy volunteers

Randomization of Botox for Stent Pain and Irritative Voiding Symptoms

NCT02078895
Conditions
Lower Urinary Tract Discomfort, Stent Pain
Interventions
Botox
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Orange, California
Conditions
Bladder Exstrophy, Urinary Incontinence
Interventions
MDC
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

TTNS vs PTNS in a County Hospital System.

NCT07353944
Conditions
Overactive Bladder
Interventions
Tibial nerve stimulation
Device
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Conditions
Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
Interventions
Not listed
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
21
States / cities
Oceanside, California • San Diego, California • San Jose, California + 15 more
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Conditions
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
SNS-101 (anti-VISTA), Cemiplimab
Drug
Lead sponsor
Sensei Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
Conditions
Asymptomatic Hyperuricemia
Interventions
Verinurad, Febuxostat, Dapagliflozin, Dapagliflozin matched placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Conditions
Stress Urinary Incontinence, Urge Incontinence, Urge and Stress, Overactive Bladder
Interventions
BTL EMSELLA Active treatment, BTL EMSELLA Sham Treatment
Device
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts